Substance / Medication

Oxprenolol

Overview

Active Ingredient
oxprenolol
RxNorm CUI
7801

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Determination of oxprenolol, methandienone and testosterone in meat samples by UHPLC-Q-ToF.
Temerdashev A, Dmitrieva E, Azaryan A et al. · Heliyon · 2023
PMID: 36816264OtherFull text (PMC)
DETERMINATION OF SOTALOL, OXPRENOLOL AND LABETALOL IN BINARY MIXTURES AND IN SPIKED HUMAN SERUM BY DERIVATIVE SPECTROPHOTOMETRIC METHOD.
Stolarczyk Mariusz, Apola Anna, Malanka Anna et al. · Acta Pol Pharm · 2017
PMID: 29474765Other
Molecular dynamics simulations of Oxprenolol and Propranolol in a DPPC lipid bilayer.
Azizi Khaled, Koli Mokhtar Ganjali · J Mol Graph Model · 2016
PMID: 26851866Other
High sensitivity analysis of oxprenolol in urine by capillary electrophoresis with C18 packed on-line preconcentrator.
De Rossi Antonella, Desiderio Claudia · J Chromatogr B Analyt Technol Biomed Life Sci · 2006
PMID: 16364697Other
Chiral separation of oxprenolol by affinity electrokinetic chromatography-partial filling technique using human serum albumin as chiral selector.
Martínez-Gómez M A, Martínez-Pla J J, Sagrado S et al. · J Pharm Biomed Anal · 2005
PMID: 15927439Other
Adrenaline enhances nociceptive and motor blockades by intrathecal carteolol and oxprenolol in rats.
Chiu Chong-Chi, Liu Kuo-Sheng, Liu Chieh-Yu et al. · Fundam Clin Pharmacol · 2025
PMID: 40016856Preclinical
The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model.
Yuan Luping, Springer Jochen, Palus Sandra et al. · J Cachexia Sarcopenia Muscle · 2023
PMID: 36346141PreclinicalFull text (PMC)
Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats.
Bradamante Vlasta, Krnić Zarka, Zrinski Renata et al. · Arzneimittelforschung · 2006
PMID: 16572919Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Oxprenolol (substance)
SNOMED CT
387583006
UMLS CUI
C0030040
RxNorm CUI
7801

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.